Trident Texofab Ltd — Updates, 04-06-2025: Company Update

Trident Texofab Limited has announced a board meeting outcome approving the conversion of 4,81,907 warrants into an equal number of equity shares at Rs. 70 each, including a Rs. 60 premium per share. The company received Rs. 2.53 Cr as the balance payment for the conversion from non-promoter public investors. Post allotment, the paid-up capital increased to Rs. 14.99 Cr comprising 1.5 crore equity shares. There are still 9.11 lakh warrants pending conversion, which holders can convert by paying the remaining amount within 18 months. This share infusion strengthens equity and supports future growth.